Protocol for fungal infection following the induction of epithelial cell loss in larval zebrafish.
| Autor: | Wurster S; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Ruiz OE; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Tatara AM; Medical Scientist Training Program, Baylor College of Medicine, Houston, TX 77030, USA., Kontoyiannis DP; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Eisenhoffer GT; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; Genetics and Epigenetics Graduate Program, MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | STAR protocols [STAR Protoc] 2021 Nov 19; Vol. 2 (4), pp. 100963. Date of Electronic Publication: 2021 Nov 19 (Print Publication: 2021). |
| DOI: | 10.1016/j.xpro.2021.100963 |
| Abstrakt: | Epithelia provide the first line of defense against foreign pathogens, and disruption of tissue homeostasis frequently allows for opportunistic infections. Here we provide a protocol for induction of epithelial cell loss in zebrafish larvae, followed by infection with fungal pathogens. Details are provided for monitoring larval survival after infection, assessment of fungal burden, and prophylactic treatment with antifungal compounds. Limitations of the protocol include potential antifungal toxicity and high fungal inoculums to induce lethal infection with some pathogenic fungal species. For complete details on the use and execution of this protocol, please refer to Wurster et al. (2021). Competing Interests: D.P.K. reports honoraria and research support from Gilead Sciences, received consultant fees from Astellas Pharma and Gilead Sciences, and is a member of the Data Review Committee of Cidara Therapeutics. All other authors declare no competing interests. (© 2021 The Authors.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|